Home/galderma/Michele Libonati

ML

Michele Libonati

Chief Operating Officer

Therapeutic Areas

Dermatology Aesthetic Medicine

galderma Pipeline

Drug	Indication	Phase
Twymeeg (nemolizumab)	Pruritus in Atopic Dermatitis	Filed
Sculptra	Body Contouring (Buttock Enhancement)	Investigational
GM-2505	Undisclosed Inflammatory Dermatosis	Phase 1

Leadership Team at galderma

Flemming Ørnskov

Chief Executive Officer

Chief Financial Officer

Baldo Scassellati Sforzolini

Global Head of Research & Development

Fabrice Lefebvre

Chief Commercial Officer

View full galderma profile